Full
Outline
This study aimed to screen a strain with high cholesterol-lowering effect from traditional fermented yak yogurt in western Sichuan province and explore its therapeutic effect on hypercholesterolemia. This study focused on 295 strains of lactic acid bacteria isolated from traditional fermented yak yogurt in Western Sichuan, and the lactic acid bacteria with high cholesterol-lowering ability were screened by ferric ammonium sulfate method and o-phthalaldehyde method, and the in vitro probiotic characterization test and safety evaluation were carried out, and the cholesterol-lowering effect of the strains was evaluated by establishing a mouse model of hypercholesterolemia induced by high-fat diet. The screening revealed four strains exhibiting favorable cholesterol-reducing efficiency and efficacy isolated from 295 lactic acid bacteria. Among the 4 strains, strain 166 had the highest survival rate in simulated gastric fluid tolerance assay test, and the number of viable bacteria remained above 5.3×108 CFU/mL after 3 h of incubation in the simulated intestinal fluid, and it possessed a good bile salt tolerance performance, with a hydrophobic capacity of up to 62.3%, auto-aggregation capacity of 18.65%, which was identified as Limosilactobacillus fermentum. In addition, strain 166 was evaluated negatively for harmful metabolites, no hemolysis phenomenon, no gelatin liquefaction, and showed some resistance to eight antibiotics, which showed good in vitro probiotic properties and safety. In vivo experiments in animals showed that Limosilactobacillus fermentum 166 could significantly reduce the serum total cholesterol, triglycerides, low-density lipoprotein cholesterol levels and atherosclerosis index of mice, effectively increase the content of serum high-density lipoprotein cholesterol, and effectively improve the Lee's index, liver index, perirenal fat index and abdominal fat index. Therefore, Limosilactobacillus fermentum 166 has the potential to be developed as a functional probiotic product, providing data support for the prevention and adjunctive therapy of hypercholesterolemia.
127
54
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
